Data / Form D filings / Chase Pharmaceuticals Corp
Chase Pharmaceuticals Corp: Form D filings
Chase Pharmaceuticals Corp, a pharmaceuticals company in Washington, DC, filed 7 Form D notices with the SEC between 2011 and 2016. The latest, on March 28, 2016, reports $12 million sold of a $12 million offering to 14 investors.
Find out what Chase Pharmaceuticals Corp does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1825 K STREET, NW, SUITE 510, Washington, DC, 20006
- Phone
- (202) 223-7002
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1509008
The full lists. Form D filings in District of Columbia: 247 rows, $12.35, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 28, 2016 | New notice | $11,974,004 | $11,974,004 | $0 | 14 | Mar 14, 2016 | sec.gov |
| Feb 17, 2016 | Amendment | $3,500,000 | $3,500,000 | $0 | 13 | Aug 5, 2015 | sec.gov |
| Feb 17, 2016 | New notice | $106,650 | $0 | $106,650 | 3 | Dec 11, 2015 | sec.gov |
| Feb 16, 2016 | New notice | $612,500 | $0 | $612,500 | 1 | Jan 13, 2016 | sec.gov |
| Aug 20, 2015 | New notice | $3,000,000 | $3,000,000 | $0 | 12 | Aug 5, 2015 | sec.gov |
| May 30, 2014 | New notice | $8,586,000 | $6,137,999 | $2,448,001 | 6 | May 9, 2014 | sec.gov |
| Jan 5, 2011 | New notice | $1,200,000 | $1,200,000 | $0 | 1 | Nov 23, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kathleen N. Clarence-Smith | Executive Officer | |
| Vikram M. Sudarsan | Director | |
| Raphael M. Wisniewski | Director | |
| Stephen N. Cunningham | Director | |
| Nayan Greg Parekh | Director | |
| Karoly N. Nikolich | Director | |
| John M. Reher | Director | |
| Thomas N. Chase | Executive Officer, Director |
Every Form D from the week of Mar 28, 2016 · All recent filings in District of Columbia · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Chase Pharmaceuticals Corp reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.